Lysophosphatidylcholines are associated with P-tau181 levels in early stages of Alzheimer’s Disease.

We investigated systemic biochemical changes in Alzheimer’s disease (AD) by investigating the relationship between circulating plasma metabolites and both clinical and biomarker-assisted diagnosis of AD.